Prostate cancer has long been considered immune-cold — a tumour type that stubbornly resists the immune therapies that have transformed treatment for other cancers like melanoma and lung cancer.
A new drug may have just changed that.
Early results from a Phase 1 clinical trial of **VIR-5500**, presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in February 2026, have been described by leading oncologists as 'unprecedented,' 'stunning,' and 'remarkable.' The findings were published by Vir Biotechnology.
## What Is VIR-5500?
VIR-5500 is a **PSMA-targeting dual-masked T-cell engager**. That sounds complicated — but the concept is elegant.
Prostate cancer cells express high levels of a protein called prostate-specific membrane antigen (PSMA). VIR-5500 is designed to find those PSMA-tagged cells and bring the body's own killer T-cells into direct contact with them.
The clever part: VIR-5500 uses a **cloaking technology (PRO-XTEN)** that keeps the drug inactive while it is in the bloodstream. It only unmasks and activates when it reaches the tumour microenvironment. This dramatically reduces the systemic side effects that have plagued other T-cell engagers — problems like cytokine storms that can cause severe illness.
The drug also lingers in the bloodstream longer than typical T-cell engagers, meaning patients may need fewer infusions.
## The Results
The trial enrolled **58 men** with metastatic castration-resistant prostate cancer (mCRPC) — advanced disease that had already stopped responding to multiple prior treatments. These are patients for whom few options remain.
At the highest dose cohorts, the results were striking:
- **82%** of patients saw their PSA levels drop by at least 50% - **53%** saw PSA levels fall by 90% or more - **45%** of evaluable patients showed measurable tumour shrinkage on imaging - **88%** of all patients experienced only very mild side effects - **One 63-year-old man** with 14 cancerous liver metastases saw **all 14 resolve completely** after six treatment cycles - **Another patient**, aged 77, reached **undetectable PSA levels** after 17 cycles
No dose-limiting toxicities have been observed.
## Why This Is Different
Prostate cancer is the **second most common cancer in men globally**, with 1.4 million new diagnoses per year. At the advanced, metastatic stage, it has been notoriously resistant to the immune checkpoint inhibitors and CAR-T cell therapies that have transformed other cancers.
'We have never seen anything like this in prostate cancer,' said **Professor Johann de Bono** of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, who led the study. He called the results 'unprecedented for a disease that has been immune-cold for so long.'
For the men in the trial — many of whom had exhausted conventional options — the 82% PSA response rate and the complete disappearance of one patient's 14 tumours represent something more than data. They represent time.
## What Comes Next
Vir Biotechnology plans to begin **dose-expansion cohorts** in Q2 2026, enrolling both late-line and earlier-line prostate cancer patients. A **pivotal Phase 3 trial** is planned for 2027.
If the results hold in larger studies, VIR-5500 could become the first immunotherapy to genuinely work for prostate cancer — and potentially a new template for treating other immune-cold tumours. 💙
*Sources: Vir Biotechnology (February 2026) · The Guardian · The Independent · ASCO Genitourinary Cancers Symposium 2026 · Institute of Cancer Research / Royal Marsden NHS · ClinicalTrials.gov NCT05997615*
